Tsuruha Holdings (3391) Q1 2027 earnings summary
Event summary combining transcript, slides, and related documents.
Q1 2027 earnings summary
8 Jul, 2026Executive summary
Operating income grew approximately 40% year-over-year for both groups, with TSURUHA Group up ¥5.0 billion and WELCIA Group up ¥3.6 billion.
Completed business integration with WELCIA HOLDINGS on December 1, 2025, and launched a new Medium-Term Management Plan (FY2/2027–FY2/2029) focused on value creation and integration synergies.
Net sales increased 4.8% year-over-year for both groups, with consolidated net sales reaching ¥636.9 billion.
Opened 36 new stores and closed 47, resulting in 5,665 directly managed stores as of May 31, 2026.
Actively renovated stores and expanded the Drug & Food model to increase customer visits and trade area reach.
Financial highlights
Net sales for the three months ended May 31, 2026, were ¥636,886 million, up 133.7% year-over-year.
Operating income rose 94.3% year-over-year to ¥24,229 million; ordinary income increased 86.8% to ¥24,390 million.
TSURUHA Group: Net sales ¥285.6 billion (+4.8% YoY), operating income ¥17.5 billion (+40.1% YoY), net income ¥11.6 billion (+4.1% YoY), EBITDA ¥22.1 billion (+29.5% YoY).
WELCIA Group: Net sales ¥351.3 billion (+4.8% YoY), operating income ¥12.3 billion (+41.8% YoY), net income ¥7.4 billion (+22.0% YoY), EBITDA ¥17.4 billion (+14.5% YoY).
Net income attributable to owners of the parent was ¥13,477 million, up 21.3% year-over-year.
Outlook and guidance
Full-year forecast for FY ending February 28, 2027: net sales ¥2,555,000 million, operating income ¥99,400 million, net income attributable to owners of the parent ¥41,500 million, and basic EPS ¥91.62.
Integration synergies are on track, with a first-year synergy target of ¥15.0 billion.
No revisions to previously announced earnings forecasts.
Continued focus on maximizing integration benefits through organizational and logistics initiatives.
Latest events from Tsuruha Holdings
- Medium-term plan targets ¥2.7 trillion sales by FY2/29 with integrated, quality-focused growth.3391
Investor presentation9 Apr 2026 - Net income surpassed plan, fueled by integration gains and strong sales growth.3391
Q4 20269 Apr 2026 - Nine-month net sales were ¥833,383 million, with WELCIA integration completed.3391
Q3 20268 Jan 2026 - Profits and sales beat targets, with integration and stock split amid sector challenges.3391
Q2 202610 Dec 2025 - Net sales and operating income surpassed targets amid robust food and pharmacy growth and integration plans.3391
Q1 202610 Jul 2025 - Transitional period saw solid sales and profit, with FY2026 guidance projecting further growth.3391
Q4 202530 Jun 2025 - Q1 profit and sales rose, outlook steady despite one-time costs from fiscal year change.3391
Q1 202513 Jun 2025 - Sales rose 5.9% but net income dipped on impairment; FY2025 outlook is for strong profit growth.3391
Q4 202413 Jun 2025 - FY2025 net sales reached ¥845.6B; FY2026 forecast sees growth to ¥1,113.4B.3391
Q3 20256 Jun 2025